Literature DB >> 1756726

HIV-1 Tat protein promotes formation of more-processive elongation complexes.

R A Marciniak1, P A Sharp.   

Abstract

The Tat protein of HIV-1 trans-activates transcription in vitro in a cell-free extract of HeLa nuclei. Quantitative analysis of the efficiency of elongation revealed that a majority of the elongation complexes generated by the HIV-1 promoter were not highly processive and terminated within the first 500 nucleotides. Tat trans-activation of transcription from the HIV-1 promoter resulted from an increase in processive character of the elongation complexes. More specifically, the analysis suggests that there exist two classes of elongation complexes initiating from the HIV promoter: a less-processive form and a more-processive form. Addition of purified Tat protein was found to increase the abundance of the more-processive class of elongation complex. The purine nucleoside analog, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) inhibits transcription in this reaction by decreasing the efficiency of elongation. Surprisingly, stimulation of transcription elongation by Tat was preferentially inhibited by the addition of DRB.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1756726      PMCID: PMC453171          DOI: 10.1002/j.1460-2075.1991.tb04997.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  61 in total

1.  5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription elongation by RNA polymerase II in vitro.

Authors:  L A Chodosh; A Fire; M Samuels; P A Sharp
Journal:  J Biol Chem       Date:  1989-02-05       Impact factor: 5.157

2.  HIV-1 tat trans-activation requires the loop sequence within tar.

Authors:  S Feng; E C Holland
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

3.  A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells.

Authors:  D L Bentley; M Groudine
Journal:  Nature       Date:  1986 Jun 12-18       Impact factor: 49.962

4.  Missense mutations in an infectious human immunodeficiency viral genome: functional mapping of tat and identification of the rev splice acceptor.

Authors:  M R Sadaie; J Rappaport; T Benter; S F Josephs; R Willis; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

6.  Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation.

Authors:  M F Laspia; A P Rice; M B Mathews
Journal:  Genes Dev       Date:  1990-12       Impact factor: 11.361

7.  Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.

Authors:  B R Cullen
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

8.  Transcriptional arrest within the first exon is a fast control mechanism in c-myc gene expression.

Authors:  D Eick; G W Bornkamm
Journal:  Nucleic Acids Res       Date:  1986-11-11       Impact factor: 16.971

9.  Inhibitory effect of 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole on a protein kinase.

Authors:  R Zandomeni; R Weinmann
Journal:  J Biol Chem       Date:  1984-12-10       Impact factor: 5.157

10.  Action of dichlorobenzimidazole riboside on RNA synthesis in L-929 and HeLa cells.

Authors:  I Tamm; R Hand; L A Caliguiri
Journal:  J Cell Biol       Date:  1976-05       Impact factor: 10.539

View more
  156 in total

Review 1.  Mechanism and regulation of transcriptional elongation by RNA polymerase II.

Authors:  D Reines; R C Conaway; J W Conaway
Journal:  Curr Opin Cell Biol       Date:  1999-06       Impact factor: 8.382

Review 2.  P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.

Authors:  D H Price
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

3.  R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs.

Authors:  A M Trubetskoy; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

4.  Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR.

Authors:  A V Filikov; V Mohan; T A Vickers; R H Griffey; P D Cook; R A Abagyan; T L James
Journal:  J Comput Aided Mol Des       Date:  2000-08       Impact factor: 3.686

5.  Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences.

Authors:  Cyril F Bourgeois; Young Kyeung Kim; Mark J Churcher; Michelle J West; Jonathan Karn
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

6.  The transcription elongation factor CA150 interacts with RNA polymerase II and the pre-mRNA splicing factor SF1.

Authors:  A C Goldstrohm; T R Albrecht; C Suñé; M T Bedford; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

7.  Ubiquitination of RNA polymerase II large subunit signaled by phosphorylation of carboxyl-terminal domain.

Authors:  A Mitsui; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

8.  A nucleolar TAR decoy inhibitor of HIV-1 replication.

Authors:  Alessandro Michienzi; Shirley Li; John A Zaia; John J Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-10       Impact factor: 11.205

9.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

10.  Circular dichroism and molecular modeling yield a structure for the complex of human immunodeficiency virus type 1 trans-activation response RNA and the binding region of Tat, the trans-acting transcriptional activator.

Authors:  E P Loret; P Georgel; W C Johnson; P S Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.